{"organizations": [], "uuid": "3709b3668a0d851cef5810ff99a5ae89f5aaf84d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-immunoprecise-to-invest-in-single/brief-immunoprecise-to-invest-in-single-cells-foundational-technology-idUSFWN1PH0OB", "country": "US", "domain_rank": 408, "title": "BRIEF-ImmunoPrecise To Invest In Single Cell's Foundational Technology", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T15:56:00.000+02:00", "replies_count": 0, "uuid": "3709b3668a0d851cef5810ff99a5ae89f5aaf84d"}, "author": "", "url": "https://www.reuters.com/article/brief-immunoprecise-to-invest-in-single/brief-immunoprecise-to-invest-in-single-cells-foundational-technology-idUSFWN1PH0OB", "ord_in_thread": 0, "title": "BRIEF-ImmunoPrecise To Invest In Single Cell's Foundational Technology", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "undational technology reuters", "sentiment": "none"}, {"name": "immunoprecise antibodies ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 22, 2018 / 1:57 PM / in 20 minutes BRIEF-ImmunoPrecise To Invest In Single Cell's Foundational Technology Reuters Staff \nJan 22 (Reuters) - Immunoprecise Antibodies Ltd: \n* IMMUNOPRECISE TO STRATEGICALLY INVEST IN FOUNDATIONAL NEXT GENERATION ANTIBODY DISCOVERY TECHNOLOGY \n* IMMUNOPRECISE ANTIBODIES - ‍AGREED TO INVEST $5 MILLION IN EXPANSION & DEVELOPMENT OF PRODUCTION CAPABILITY FOR SINGLE CELL‘S FOUNDATIONAL TECHNOLOGY​ \n* IMMUNOPRECISE ANTIBODIES - INVESTMENT WILL RESULT IN CO OWNING ABOUT 10% OF ISSUED AND OUTSTANDING SHARES OF SINGLE CELL Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T15:56:00.000+02:00", "crawled": "2018-01-22T16:02:56.006+02:00", "highlightTitle": ""}